Clinical trials: Endocrine Toxicity
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Islet Cell Adenoma, Neoplasm Metastasis
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors.
- Conditions
- Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
- Trial name
- NCT00001165
- Testing
- combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
This phase I trial is studying the side effects and best dose of cisplatin given together with paclitaxel in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication
- Trial name
- NCT00814086
- Testing
- Paclitaxel, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer.
- Conditions
- Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity, Chemo-brain, Cancer
- Trial name
- MyBrain (NCT05840575)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
RATIONALE: Chemotherapy drugs use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Trial name
- NCT00003811
- Testing
- bleomycin sulfate, amifostine trihydrate, cisplatin
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 27 people
- Sponsor
- Children's Oncology Group
Cancer
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
RATIONALE: A step-by-step procedure may help health care practitioners diagnose and treat cancer patients with bowel injury symptoms caused by radiation therapy.
- Trial name
- NCT00737230
- Testing
- educational intervention, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Hyperprolactinemia, Puberty Disorders
PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
The objectives of this study are: 1. To determine the prevalence and degree of hyperprolactinemia in children and adolescents aged 7-18 years receiving antipsychotic medications 2.
- Conditions
- Hyperprolactinemia, Puberty Disorders, Metabolic Syndrome, Growth Disorders
- Trial name
- PROSA (NCT05033119)
- Where
- 3 sites in Denmark
- Volunteers
- 90 people
- Sponsor
- Ulla Schierup Nielsen
Solid Tumor, Thyroid Cancer
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Objectives: Primary objectives: To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors.
- Trial name
- NCT00354523
- Testing
- Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Dent Disease
Evaluation of the Release of Monomers From Composite Bonding Resins in Orthodontics
In recent decades, the field of public health has become increasingly interested in endocrine disruptors, and their effects on humans.
- Trial name
- MONORTHO (NCT04459013)
- Testing
- Salivary samples
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anal Cancer, Bladder Cancer
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
RATIONALE: Fiber may lessen bowel side effects caused by radiation therapy. It is not yet known whether a high-fiber diet is more effective than a low-fiber diet in preventing bowel side effects caused by radiation therapy.
- Conditions
- Anal Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer
- Trial name
- NCT01170299
- Testing
- dietary intervention, laboratory biomarker analysis, gastrointestinal complications management/prevention
- Where
- United Kingdom
- Volunteers
- 177 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single…
- Conditions
- Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer
- Trial name
- ICEMELT (NCT04631731)
- Testing
- Blood screening, Tissue screening
- Where
- 2 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Western Sydney Local Health District
Non-seminomatous Testicular Cancer
Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity
BACKGROUND: Evidence has emerged that patients cured with cisplatin-bleomycin chemotherapy from disseminated testicular cancer (TC) develop a large number of cardiovascular risk factors (CRF) several years later.
- Trial name
- NCT00161174
- Where
- Netherlands
- Volunteers
- 173 people
- Sponsor
- University Medical Center Groningen
Schizophrenia, Antipyretics Toxicity
Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment
Objective: Hyperprolactinemia(HPRL) which can result in a series of prolactin-related symptoms is a frequent adverse effect of antipsychotics.
- Conditions
- Schizophrenia, Antipyretics Toxicity, Prolactin Excess
- Trial name
- NCT04002258
- Testing
- Antipsychotic
- Where
- China
- Volunteers
- 10,363 people
- Sponsor
- Shanghai Mental Health Center
Neoplasms
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy
The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry…
- Trial name
- HARMONIC-RT (NCT04746729)
- Testing
- No intervention
- Where
- 5 sites in Belgium, Denmark and 2 more
- Volunteers
- 2,670 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Ovarian Cancer
PRO for Fighting FT in Ovarian Cancer
Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for OC patients does produce tangible changes of financial distress over the…
- Trial name
- MITO45-ProFFiT (NCT06032975)
- Testing
- Questionnaires
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- National Cancer Institute, Naples
Retinal Dystrophies, Age-related Macular Degeneration
Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases
Using an adaptive optics imaging device, retinal structures are observed in healthy and diseased subjects.
- Conditions
- Retinal Dystrophies, Age-related Macular Degeneration, Arterial Hypertension, Diabetes
- Trial name
- iPhot (NCT01546181)
- Where
- France
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Peritoneum Cancer, Peritoneum Neoplasm
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases.
- Conditions
- Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer, Pleural Effusion
- Trial name
- PIPACRegis (NCT03210298)
- Testing
- PIPAC
- Where
- 16 sites in Argentina, Australia and 11 more
- Volunteers
- 1,000 people
- Sponsor
- Sabine Rhode
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center